Treatment of pulmonary hypertension: bench to bedside.
Pulmonary arterial hypertension is an orphan disease and a model for drug developments over recent years. Expert centers have focused basic science on the pulmonary vasculature and the right ventricle, followed by a direct transfer of innovative concepts to clinical research. Successful examples for translational experimentation are the endothelin receptor antagonists, prostacyclin receptor agonists, and the activators of soluble guanylate cyclase. On the other hand, there have been failures such as vasoactive intestinal peptide, statins, and escitalopram. Several new drugs and gene therapy are under investigation, thus significant advances are anticipated.
Applied Cachexia Research, Charité Universitaetsmedizin Berlin, Berlin, Germany.
Jochen
J
Springer
Mitja
M
Lainscak
Barbara
B
Salobir
Irene M
IM
Lang
D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015897:Comorbidity; D065128:Endothelin Receptor Antagonists; D004789:Enzyme Activation; D015316:Genetic Therapy / Q000639:trends; D006162:Guanylate Cyclase / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D018384:Oxidative Stress; D011788:Quality of Life; D044006:Receptors, Epoprostenol / Q000819:agonists; D057170:Translational Research, Biomedical
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D044006:Receptors, Epoprostenol; D006162:Guanylate Cyclase